Figure 2 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

<p>Graphs depicting the density of macrophage subsets pre- and posttreatment with TRK-950. Tumor specimens obtained with core-needle biopsies at the screening and C1D22 time points were subjected to multi-immunofluorescence to detect macrophage infiltrates. Quantitative analyses were performed on digital images of CD68 and CD163 staining. <b>A,</b> total CD68<sup>+</sup> cells; (<b>B</b>) CD68<sup>+</sup>/CD163<sup>−</sup> subsets; (<b>C</b>) CD68<sup>+</sup>/CD163<sup>+</sup> subsets. Error bars indicate SD. C1D22, cycle 1 day 22; SCR, screening.</p>